Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Clinical trial NCT04806035 · TERMINATED
Trial details
- NCT number
- NCT04806035
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-28
- Primary completion
- 2024-06-12
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.